BR112016009901A8 - uso de citrato férrico - Google Patents

uso de citrato férrico Download PDF

Info

Publication number
BR112016009901A8
BR112016009901A8 BR112016009901A BR112016009901A BR112016009901A8 BR 112016009901 A8 BR112016009901 A8 BR 112016009901A8 BR 112016009901 A BR112016009901 A BR 112016009901A BR 112016009901 A BR112016009901 A BR 112016009901A BR 112016009901 A8 BR112016009901 A8 BR 112016009901A8
Authority
BR
Brazil
Prior art keywords
iron
increase
reduce
levels
need
Prior art date
Application number
BR112016009901A
Other languages
English (en)
Inventor
Poradosu Enrique
F Oliviero James Iii
Bentsur Ron
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of BR112016009901A8 publication Critical patent/BR112016009901A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

a presente invenção refere-se a métodos para administrar citrato férrico de modo a reduzir e/ou controlar os níveis séricos de fósforo, aumentar os níveis séricos de bicarbonato, melhorar um ou mais parâmetros de armazenamento de ferro (por exemplo, aumentar os níveis séricos de ferritina, aumentar a saturação de transferrina (tsat), aumentar a concentração de hemoglobina), aumentar a absorção de ferro, manter as reservas de ferro, tratar a deficiência de ferro, tratar anemia, reduzir a necessidade de ferro iv, reduzir a necessidade de agentes estimuladores de eritropoiese (aees), e/ou reduzir a mortalidade morbidade relacionadas a eventos cardíacos adversos em pacientes com doença renal crônica.
BR112016009901A 2013-11-04 2014-11-03 uso de citrato férrico BR112016009901A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899866P 2013-11-04 2013-11-04
PCT/US2014/063643 WO2015066593A1 (en) 2013-11-04 2014-11-03 Ferric citrate for reducing cardiac failure in chronic kidney disease patients

Publications (1)

Publication Number Publication Date
BR112016009901A8 true BR112016009901A8 (pt) 2020-04-14

Family

ID=53005244

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016009901A BR112016009901A8 (pt) 2013-11-04 2014-11-03 uso de citrato férrico

Country Status (15)

Country Link
US (2) US20160256486A1 (pt)
EP (2) EP3747432A1 (pt)
JP (3) JP2016535780A (pt)
KR (1) KR102392441B1 (pt)
CN (1) CN105873583A (pt)
AU (1) AU2014341975A1 (pt)
BR (1) BR112016009901A8 (pt)
CA (1) CA2928200A1 (pt)
EA (1) EA201690926A1 (pt)
HK (1) HK1223031A1 (pt)
IL (1) IL245317A0 (pt)
MX (1) MX2016005734A (pt)
SG (1) SG11201603091QA (pt)
TW (2) TW202203910A (pt)
WO (1) WO2015066593A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010276242B2 (en) 2009-07-21 2014-05-29 Keryx Biopharmaceuticals, Inc. Ferric citrate dosage forms
ES2733493T3 (es) 2013-06-05 2019-11-29 Tricida Inc Polímeros de unión a protones para la administración oral
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
CA3164664A1 (en) 2014-12-10 2016-06-16 Tricida, Inc. Proton-binding polymers for oral administration
US20190209607A1 (en) 2016-05-06 2019-07-11 Tricida, Inc. Compositions for treating acid-base disorders
EP3703706A4 (en) 2017-11-03 2022-04-27 Tricida Inc. COMPOSITIONS AND METHOD FOR TREATING ACID-BASE DISORDERS
CA3117071A1 (en) 2018-10-29 2020-05-07 Pharmacosmos Holding A/S Treating iron deficiency with ferric carboxymaltose
EA202191858A1 (ru) * 2019-06-12 2021-11-12 Фармакосмос Холдинг А/С Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
TW202313072A (zh) * 2021-05-27 2023-04-01 美商凱立克斯生物製藥股份有限公司 檸檬酸鐵之兒科調配物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE351366B (pt) * 1965-06-08 1972-11-27 Teikoku Hormone Mfg Co Ltd
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
US8093423B2 (en) * 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
CA2619591C (en) 2005-08-18 2020-03-24 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
KR20080106506A (ko) * 2006-01-30 2008-12-08 글로보아시아 엘엘씨 만성 신장병의 치료 방법
AU2007210096B2 (en) 2006-01-30 2013-10-24 Panion & Bf Biotech Inc. Method of reversing, preventing, delaying or stabilizing soft tissue calcification
AU2010276242B2 (en) 2009-07-21 2014-05-29 Keryx Biopharmaceuticals, Inc. Ferric citrate dosage forms
EP2590655B1 (en) * 2010-07-07 2015-06-24 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
CA2876982A1 (en) * 2012-06-21 2013-12-27 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of chronic kidney disease patients

Also Published As

Publication number Publication date
EP3065734A4 (en) 2017-05-17
IL245317A0 (en) 2016-06-30
TW202203910A (zh) 2022-02-01
MX2016005734A (es) 2016-11-08
JP2016535780A (ja) 2016-11-17
HK1223031A1 (zh) 2017-07-21
TW201609088A (zh) 2016-03-16
CN105873583A (zh) 2016-08-17
EP3747432A1 (en) 2020-12-09
JP2021073230A (ja) 2021-05-13
SG11201603091QA (en) 2016-05-30
KR102392441B1 (ko) 2022-05-02
JP6828100B2 (ja) 2021-02-10
CA2928200A1 (en) 2015-05-07
JP2019206562A (ja) 2019-12-05
AU2014341975A1 (en) 2016-05-19
EA201690926A1 (ru) 2016-09-30
US20160256486A1 (en) 2016-09-08
KR20160096597A (ko) 2016-08-16
TWI744215B (zh) 2021-11-01
WO2015066593A1 (en) 2015-05-07
US20190307791A1 (en) 2019-10-10
EP3065734A1 (en) 2016-09-14

Similar Documents

Publication Publication Date Title
BR112016009901A8 (pt) uso de citrato férrico
MX2014015615A (es) Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica.
BR112014007487A2 (pt) peptídeos terapêuticos
BR112015021576A2 (pt) peptídeos terapêuticos
BR112014016643A2 (pt) estruturas fibrosas contendo ativo com múltiplas regiões tendo densidades diferentes
BR112014029752A2 (pt) uso de n-metil-n-acilglucaminas como estabilizadores de frio em soluções de tensoativos
WO2014141152A3 (en) Low concentration antibody formulations
BR112014031866A2 (pt) Composição farmacêutica intramamária para utilização no tratamento ou prevenção da mastite em um mamífero não humano e composição farmacêutica de fosfomicina e de pelo menos um anti-microbiano
EA201600474A1 (ru) Комбинированная терапия с использованием антитела к ang2 и агониста cd40
EA201590849A1 (ru) Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови
BR112015012014A2 (pt) proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb)
EA201491584A1 (ru) Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
BR112014010590A2 (pt) 18-metil-6,7-metilen-3-oxo-17-pregn-4-eno-21,17?-carbolactonas, preparações farmacêuticas contendo os compostos mencionados e seu uso na terapia da endometriose
EA201591618A1 (ru) Замещенные имидазопиридазины
BR112015025955A2 (pt) tratamentos anticancerosos com anticorpos anti-egfr apresentando uma baixa fucosilação
EA201591424A1 (ru) Способы лечения дефицита железа растворимым пирофосфатом железа
BR112014029954A2 (pt) tratamento de tumores sólidos usando coenzima q10
PH12015501709A1 (en) Administration of an-activin-a compound to a subject
EA201500363A8 (ru) Человеческие анти-vegfr-2/kdr-антитела
PH12015502163A1 (en) Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, casein phosphopeptide, and protein
BR112015020199A2 (pt) usos terapêuticos para anticorpos de vegfr1
BR112014007172A2 (pt) aglutinante para a formação de produtos baseados em partículas ou laminados
BR112015032068A2 (pt) composição para o tratamento dedoenças renais progressivas
BR112014029308A2 (pt) um método de melhorar a função hepática

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL